Who is eligible for clinical trial NCT05113251?

Participants must meet protocol criteria for Breast Neoplasms. Confirm exact inclusion and exclusion requirements with the study coordinator.

Does clinical trial NCT05113251 provide travel or cost reimbursement?

Check with the site coordinator at the participating facility for travel and lodging stipend availability, and for which routine-care costs are covered.

🏛️ Verified NIH Record • Updated 2026-08-10

Trastuzumab Deruxtecan (T-DXd) Alone or in Sequence With THP, Versus Standard Treatment (ddAC-THP), in HER2-positive Early Breast Cancer (NCT05113251)

A Phase 3 Open-label Trial of Neoadjuvant Trastuzumab Deruxtecan (T-DXd) Monotherapy or T-DXd Followed by THP Compared to ddAC-THP in Participants With High-risk HER2-positive Early-stage Breast Cancer (DESTINY-Breast11)

🔵 Active, Not Recruiting Phase3 💊 Investigational Drug / Biologic Sponsor: AstraZeneca

🩺 Plain-English Summary (8th-Grade Level)

This study will look at the efficacy and safety of trastuzumab deruxtecan (T-DXd) in a neoadjuvant setting, in high-risk, HER2-positive early non-metastatic breast cancer.

Who can join: Review the eligibility criteria below.

Location: Research Site — Springdale, Arkansas

Age range: 18 Years

🧪 Interventions in This Study

📋 "Do I Qualify?" — 1-Minute Self Screener

Instant Checklist

Full eligibility criteria are available on the official NIH protocol. View the criteria ↗

📍 All Participating Trial Locations (145 Sites)

Showing the first 25 of 145 sites.

Research Site — Springdale, Arkansas
Research Site — Beverly Hills, California
Research Site — Glendale, California
Research Site — Los Alamitos, California
Research Site — Orange, California
Research Site — New Haven, Connecticut
Research Site — Fort Wayne, Indiana
Research Site — Lexington, Kentucky
Research Site — Louisville, Kentucky
Research Site — Shreveport, Louisiana
Research Site — Minneapolis, Minnesota
Research Site — Las Vegas, Nevada
Research Site — East Brunswick, New Jersey
Research Site — Summit, New Jersey
Research Site — Commack, New York
Research Site — Durham, North Carolina
Research Site — Greenville, South Carolina
Research Site — Germantown, Tennessee
Research Site — Nashville, Tennessee
Research Site — Fort Worth, Texas
Research Site — Ogden, Utah
Research Site — Tacoma, Washington
Research Site — Goiânia,
Research Site — Ijuí,
Research Site — Natal,

💰 Cost, Insurance & Patient Rights

100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
Voluntary Participation: You may withdraw at any time without affecting your standard medical care.

More studies in Breast Neoplasms

Study of Pembrolizumab (MK-3475) Plus Chemotherapy Versus Placebo Plus Chemotherapy for HR+/HER2- Locally Recurrent Inoperable or Metastatic Breast Cancer (MK-3475-B49/KEYNOTE-B49) — Birmingham, Alabama
(Z)-Endoxifen for the Treatment of Premenopausal Women With ER+/HER2- Breast Cancer — Phoenix, Arizona
Trial of Ibrutinib Plus Trastuzumab in HER2-amplified Metastatic Breast Cancer — Dallas, Texas
Assessment of Quality of Life and Treatment Times for Patients With Invasive Type Breast Cancer in Martinique — Fort-de-France,
The IDEA Study (Individualized Decisions for Endocrine Therapy Alone) — Stanford, California

Explore by condition: All Breast Neoplasms clinical trials

💡 How to Participate

Check the checklist above to see if you may qualify.
Review the official NIH record below to find the coordinating site.
Ask about the visit schedule, what is covered at no cost, and any travel support.
Confirm with your own doctor before making a decision.

🏛️ View Official NIH Record ↗